Arthritis News and Research

Latest Arthritis News and Research

Free NYU Physician iPad app now available in iTunes store

NYU Langone Medical Center, one of the nation's premier academic medical centers, announced today the magazine of NYU School of Medicine, NYU Physician, is now available as a free iPad app in the iTunes App Store.

19 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Life Technologies Corporation and ProBioGen AG today announced the availability of Gibco Freedom Cell Line Development Kits, a new line of royalty-free products that integrate cells, reagents, culture media and protocols to bring simplicity and flexibility, eliminating up to two months in the earliest stages of new biological drug development.

17 May 2011

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.

17 May 2011

Pediatric researchers find potential tools for controlling cytokine storm

By analyzing complex interactions of the immune system in an animal study, pediatric researchers have found potential tools for controlling a life-threatening condition called a cytokine storm that may strike children who have juvenile arthritis and other autoimmune diseases.

17 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

New research shows that polymerase chain reaction testing for Borrelia burgdorferi DNA—the spirochetal bacteria transmitted by deer ticks—in joint fluid may confirm the diagnosis of Lyme arthritis, but is not a reliable indicator for active joint infection in patients whose arthritis persists after antibiotic therapy. Findings of this study are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

13 May 2011

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

The University of Manchester, GlaxoSmithKline and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research, a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of -5M from each partner over a three year period.

From The University of Manchester 12 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Scleroderma is an independent determinant for coronary calcification, study suggests

A new study by researchers in Hong Kong suggests that systemic sclerosis is an independent determinant for moderate to severe coronary calcification or atherosclerosis.

11 May 2011

Research suggests systemic sclerosis is an independent risk factor for atherosclerosis

A new study by researchers in Hong Kong suggests that systemic sclerosis is an independent determinant for moderate to severe coronary calcification or atherosclerosis. Conventional cardiovascular risk factors such as age and hypertension predispose patients with systemic sclerosis to plaque build-up in the heart arteries similar to the general population. Details of this study are now available in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

10 May 2011

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.

10 May 2011

Osiris Therapeutics net income increases to $4.0 million for first quarter 2011

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, cardiovascular, wound care and orthopedic areas, announced today its results for the first quarter ended March 31, 2011.

10 May 2011

Charisela develops breakthrough adiponectin assay

Charisela Technologies, Inc., a manufacturer of advanced assays for flow cytometers, announced today that it has developed an adiponectin assay with major advantages over existing technologies, including the elimination of dilutions. Adiponectin (Acrp30), an adipocytokine, is important in many therapeutic arenas, including type 2 diabetes, obesity, atherosclerosis, and rheumatoid arthritis.

9 May 2011

Antares Pharma first quarter total revenues increase to $3.6 million

Antares Pharma, Inc. today reported financial and operating results for the first quarter ended March 31, 2011.

9 May 2011

Tufts Health Plan now covers SBi's STAR total ankle replacement system

Small Bone Innovations, Inc. (SBi) announced today that effective July 1, 2011, Tufts Health Plan, covering approximately 742,000 members in Massachusetts and Rhode Island, is revising its reimbursement policy to cover SBi's STAR™ total ankle replacement system. The decision means that 98 percent of all privately-insured lives in Massachusetts will have access to total ankle replacement.

7 May 2011

American Gastroenterological Association, Horizon Pharma announce 2011 abstract prize recipients

The American Gastroenterological Association Research Foundation today announced Horizon Pharma's support of research awards aimed to stimulate interest in gastroenterology/hepatology research careers through competition and recognition.

6 May 2011

Kaiser Permanente awards $7.7 million as 217 grants during first quarter, 2011

Kaiser Permanente, one of the country's largest not-for-profit health care organizations, announced today that it has funded 217 grants nationwide, totaling approximately $7.7 million in the first quarter of 2011.

6 May 2011

Arthritis News and Research

Latest Arthritis News and Research

Free NYU Physician iPad app now available in iTunes store

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Pediatric researchers find potential tools for controlling cytokine storm

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

Scleroderma is an independent determinant for coronary calcification, study suggests

Research suggests systemic sclerosis is an independent risk factor for atherosclerosis

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

Osiris Therapeutics net income increases to $4.0 million for first quarter 2011

Charisela develops breakthrough adiponectin assay

Antares Pharma first quarter total revenues increase to $3.6 million

Tufts Health Plan now covers SBi's STAR total ankle replacement system

American Gastroenterological Association, Horizon Pharma announce 2011 abstract prize recipients

Kaiser Permanente awards $7.7 million as 217 grants during first quarter, 2011

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Arthritis News and Research

Latest Arthritis News and Research

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in